ARCHIVES

Gilotrif Increases PFS Compared to Erlotinib In LUX-Lung 8 Phase III Head-to-Head Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 10 | October 31, 2014

Download PDF Visit The Full Archive

Related Articles

City of Hope Selects Michael Friedman As President, CEO

May 16, 2003

NCI Cancer Prevention Fellowship Program

April 28, 2000

In Brief: Niederhuber Moves to Sanford As Surgery Chief; Jerome Urban, Breast Specialist, Dead

June 21, 1991

NCI To Fund Two Construction Grants With 42 Million From Special NIH Fund

March 2, 1990

Tykerb And Trastuzumab Showed Increase In PFS For HER2+ Breast Cancer In Study

May 30, 2008

Black-White Disparity Seen In End Of Life Treatment

November 27, 2009